Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 286

1.

Tablet preformulations of indomethacin-loaded mesoporous silicon microparticles.

Tahvanainen M, Rotko T, Mäkilä E, Santos HA, Neves D, Laaksonen T, Kallonen A, Hämäläinen K, Peura M, Serimaa R, Salonen J, Hirvonen J, Peltonen L.

Int J Pharm. 2012 Jan 17;422(1-2):125-31. doi: 10.1016/j.ijpharm.2011.10.040.

PMID:
22063301
2.

Drug delivery formulations of ordered and nonordered mesoporous silica: comparison of three drug loading methods.

Limnell T, Santos HA, Mäkilä E, Heikkilä T, Salonen J, Murzin DY, Kumar N, Laaksonen T, Peltonen L, Hirvonen J.

J Pharm Sci. 2011 Aug;100(8):3294-306. doi: 10.1002/jps.22577.

PMID:
21520084
3.

Surface chemistry and pore size affect carrier properties of mesoporous silicon microparticles.

Limnell T, Riikonen J, Salonen J, Kaukonen AM, Laitinen L, Hirvonen J, Lehto VP.

Int J Pharm. 2007 Oct 1;343(1-2):141-7.

PMID:
17600644
4.

Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole.

Kinnari P, Mäkilä E, Heikkilä T, Salonen J, Hirvonen J, Santos HA.

Int J Pharm. 2011 Jul 29;414(1-2):148-56. doi: 10.1016/j.ijpharm.2011.05.021.

PMID:
21601623
5.

Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.

Fini A, Cavallari C, Ospitali F.

Eur J Pharm Biopharm. 2008 Sep;70(1):409-20. doi: 10.1016/j.ejpb.2008.03.016.

PMID:
18621516
6.

Physicochemical performances of indomethacin in cholesteryl cetyl carbonate liquid crystal as a transdermal dosage.

Aeinleng N, Songkro S, Noipha K, Srichana T.

AAPS PharmSciTech. 2012 Jun;13(2):513-21. doi: 10.1208/s12249-012-9768-5.

7.

Incorporation of indomethacin nanoparticles into 3-D ordered macroporous silica for enhanced dissolution and reduced gastric irritancy.

Hu Y, Zhi Z, Wang T, Jiang T, Wang S.

Eur J Pharm Biopharm. 2011 Nov;79(3):544-51. doi: 10.1016/j.ejpb.2011.07.001.

PMID:
21767643
9.

Effect of surface chemistry of porous silicon microparticles on glucagon-like peptide-1 (GLP-1) loading, release and biological activity.

Huotari A, Xu W, Mönkäre J, Kovalainen M, Herzig KH, Lehto VP, Järvinen K.

Int J Pharm. 2013 Sep 15;454(1):67-73. doi: 10.1016/j.ijpharm.2013.06.063.

PMID:
23834832
10.

Modeling of latent structure of indomethacin solid dispersion tablet using Bayesian networks.

Hayashi Y, Kikuchi S, Takayama K.

Drug Dev Ind Pharm. 2011 Nov;37(11):1290-7. doi: 10.3109/03639045.2011.569935.

PMID:
21702729
11.

Physicochemical stability of high indomethacin payload ordered mesoporous silica MCM-41 and SBA-15 microparticles.

Limnell T, Heikkilä T, Santos HA, Sistonen S, Hellstén S, Laaksonen T, Peltonen L, Kumar N, Murzin DY, Louhi-Kultanen M, Salonen J, Hirvonen J, Lehto VP.

Int J Pharm. 2011 Sep 15;416(1):242-51. doi: 10.1016/j.ijpharm.2011.06.050.

PMID:
21763766
12.

Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs.

Wang F, Hui H, Barnes TJ, Barnett C, Prestidge CA.

Mol Pharm. 2010 Feb 1;7(1):227-36. doi: 10.1021/mp900221e.

PMID:
19874003
13.
14.

Tabletting of solid dispersion particles consisting of indomethacin and porous silica particles.

Takeuchi H, Nagira S, Tanimura S, Yamamoto H, Kawashima Y.

Chem Pharm Bull (Tokyo). 2005 May;53(5):487-91.

15.

A methodological evaluation and predictive in silico investigation into the multi-functionality of arginine in directly compressed tablets.

ElShaer A, Kaialy W, Akhtar N, Iyire A, Hussain T, Alany R, Mohammed AR.

Eur J Pharm Biopharm. 2015 Oct;96:272-81. doi: 10.1016/j.ejpb.2015.07.028.

PMID:
26255158
17.

The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts.

Nokhodchi A, Javadzadeh Y, Siahi-Shadbad MR, Barzegar-Jalali M.

J Pharm Pharm Sci. 2005 Jan 12;8(1):18-25.

18.
19.

Permeability assessment for solid oral drug formulations based on Caco-2 monolayer in combination with a flow through dissolution cell.

Motz SA, Schaefer UF, Balbach S, Eichinger T, Lehr CM.

Eur J Pharm Biopharm. 2007 May;66(2):286-95.

PMID:
17156983
20.

Evaluation of the physicochemical and biopharmaceutical properties of fluoro-indomethacin.

Mori MM, Airaksinen AJ, Hirvonen JT, Santos HA, Caramella CM.

Curr Drug Metab. 2013 Jan;14(1):80-9.

PMID:
22497567

Supplemental Content

Support Center